Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

The Tennessee Lady Volunteers are set to host its annual “We Back Pat” game at Food City Center on Thursday against Mississippi State.

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds. Get Real-Time ...

Israel Prize winner Prof. Michal Schwartz says her team's work fighting Alzheimer's can lead to treatments that boost immune ...